The Inlivetox project is now finished
In order to achieve these objectives the project aimed to develop a modular microfluidics-based in vitro test system, the ILT system (WP1); a system in which different cell types – each modelling a target tissue - could be maintained interact via cytokines. The target tissues chosen for this project were the GI tract, the liver and the vascular endothelium so that NP toxicity by ingestion could be modelled with the system. Subsidiary objectives in the project were the establishment of common culture conditions for the cells and test protocols for the analyses to be carried out with the ILT system (WP2). Once established, these were then to be implemented in the ILT system (WP3). Validation data were to be obtained via an in vivo study of NP toxicity by ingestion in rats carried out in parallel. Data on both biokinetics and toxic response from the target tissues were the goal of WP4. The final validation, bringing together in vivo data with new data generated by the ILT system, was the objective of WP5. The long-term objectives of the project are: -Ensure the safe development and use of NMs for commercial applications -Commercialise a test system to screen NMs for their toxicity. These two objectives are related to the foreseen impacts of the project, with future commercialisation of the InLiveTox system making it available to the whole toxicology community. For more information on the project, please see http://www.inlivetox.eu/